SUMMER

  • Research type

    Research Study

  • Full title

    SerUm and plasma MicroRNAs in Malignant ovarian gERm cell tumours

  • IRAS ID

    329236

  • Contact name

    Srdjan Saso

  • Contact email

    srdjan.saso01@imperial.ac.uk

  • Sponsor organisation

    Imperial College London

  • Duration of Study in the UK

    10 years, 0 months, 1 days

  • Research summary

    We are assessing the role of a new blood test in the monitoring and diagnosis of a specific type of ovarian cancer called a malignant ovarian germ cell tumour (MOGCT). All people diagnosed with MOGCT are recommended to have blood tests called tumour markers. These are routinely measured to help us diagnose an MOGCT, as well as to detect for early signs of recurrence. These tests are really useful in around 50% of people with MOGCT, but in many cases these tests come back normal despite the presence of cancer.

    There is a growing body of evidence about blood tests markers called ‘micro-RNAs’ in people with testicular germ cell tumours (an equivalent type of testicular cancer). These blood markers have been raised in over 97% of people with testicular germ cell tumours at the time of their diagnosis, and these levels fall when the cancer is treated and rise if the cancer recurs. There is promising evidence that these same markers could be raised in people with MOGCT. We would therefore like to explore whether we can see a rise in specific micro-RNAs in people with MOGCTs. Our aim is to develop a ‘liquid biopsy’, with hopes that we could accurately diagnose this type of cancer using a blood test in the future.

    At Imperial College Healthcare NHS Trust, we are fortunate to provide an expert ultrasound service and our team can confidently diagnose an ovarian mass as cancer or not based on its appearances. However most hospitals around the world do not have access to such expertise. Therefore, it is important to develop new ways to diagnose ovarian masses so that people all over the world can receive appropriate treatment. We therefore want to train a computer to diagnose if an ovarian mass is cancer using artificial intelligence.

  • REC name

    North East - Tyne & Wear South Research Ethics Committee

  • REC reference

    23/NE/0201

  • Date of REC Opinion

    2 Nov 2023

  • REC opinion

    Favourable Opinion